Experiment Overview
| Repository ID: | FR-FCM-ZYCC | Experiment name: | Mass Cytometry of Serial Tumor Samples from Melanoma Patients Receiving Targeted Therapy | MIFlowCyt score: | 53.75% |
| Primary researcher: | Allison Greenplate | PI/manager: | Jonathan Irish | Uploaded by: | Allison Greenplate |
| Experiment dates: | 2015-08-01 - 2017-10-03 | Dataset uploaded: | Oct 2017 | Last updated: | Oct 2018 |
| Keywords: | [T cell] [melanoma] [targeted therapy] [tumor immunology] | Manuscripts: | [30413431] |
|
|
| Organizations: |
Vanderbilt University School of Medicine, Pathology, Microbiology, and Immunology, Nashville, TN (USA)
|
||||
| Purpose: | Patients with advanced, operable BRAF mutation-positive melanoma will received GSK-2118436 (BRAF inhibitor) for two weeks, followed by the combination of GSK-2118436 and GSK-1120212 (MEK inhibitor) for two weeks, followed by surgical resection of the disease. Tumor biopsies were obtained prior to start of therapy and 2 weeks after combined GSK-2118436 and GSK-1120212. | ||||
| Conclusion: | The objective was to identify phenotypic changes in immune cells within the tumor microenvironment in response to B-RAF and MEK targeted therapy in melanoma. | ||||
| Comments: | A population of CD3+ CD4-CD8- T cells were found in melanoma, glioblastoma, and renal cell carcinoma tumors and are phenotypically distinct from CD3+ CD4-CD8- T cells in non-malignant lymphoid tissue and blood. | ||||
| Funding: | F31 CA199993-03 T32 CA009592 R25 GM062459 | ||||
| Quality control: | Fluidigm normalization beads were used to normalize signal prior to analysis. Beads were not removed by the normalization software and need to be gated out prior to analysis. | ||||
Experiment variables
| Sample Type | |
|---|---|
| · iPSCs | iPSCs.fcs |
| · Melanoma Tumor | MP004_melanom_tumor.fcs · MP013_melanom_tumor.fcs · MP015_melanom_tumor.fcs · MP029_baseline_melanom_tumor.fcs · MP029_wk4_melanom_tumor.fcs · MP031_baseline_melanom_tumor.fcs · MP031_wk4_melanom_tumor.fcs · MP032_baseline_melanom_tumor.fcs · MP032_wk4_melanom_tumor.fcs · MP034_baseline_melanom_tumor.fcs · MP034_wk4_melanom_tumor.fcs · MP039_melanom_tumor.fcs · MP049b_melanom_tumor.fcs · MP055_baseline_melanom_tumor.fcs · MP055_wk4_melanom_tumor.fcs · MP059_baseline_melanom_tumor.fcs · MP059_wk4_melanom_tumor.fcs · MP062_wk4_melanom_tumor.fcs |
| · GBM Tumor | GBM_LC-04B_Ungated.fcs · GBM_LC-06B_Ungated.fcs · GBM_W-5_Ungated.fcs |
| · RCC Tumor | RCC_29_Ungated.fcs · RCC_37_Ungated.fcs · RCC_52_Ungated.fcs |
| · Non-malignant Adenoid and Tonsil | Non-malignant_Adenoid_11.fcs · Non-malignant_Adenoid_18.fcs · Non-malignant_Adenoid_19.fcs · Non-malignant_Tonsil_19.fcs |
| Timepoints | |
|---|---|
| · 4 weeks after start of therapy | MP029_wk4_melanom_tumor.fcs · MP031_wk4_melanom_tumor.fcs · MP032_wk4_melanom_tumor.fcs · MP034_wk4_melanom_tumor.fcs · MP055_wk4_melanom_tumor.fcs · MP059_wk4_melanom_tumor.fcs · MP062_wk4_melanom_tumor.fcs |
| · baseline | MP029_baseline_melanom_tumor.fcs · MP031_baseline_melanom_tumor.fcs · MP032_baseline_melanom_tumor.fcs · MP034_baseline_melanom_tumor.fcs · MP055_baseline_melanom_tumor.fcs · MP059_baseline_melanom_tumor.fcs |
